



ECCMID 2019 conference, Amsterdam

Investor presentation Q2 2019



Introducing QIAGEN

Portfolio review

Q1 2019 results

Appendix

THE BUILDING BLOCKS OF LIFE: DNA AND RNA

CUSTOMERS RELY ON QIAGEN FOR MOLECULAR TESTING SOLUTIONS



- QIAGEN: World leader in molecular testing solutions that advance science and improve outcomes for patients

ADDRESSING THE WORLD'S MOST PRESSING CHALLENGES



Academia

How can we achieve scientific breakthroughs even faster?



Pharma

How can we develop better and safer drugs?



Applied Testing

How can we improve public safety?



Molecular Diagnostics


How can we further improve outcomes for patients?



- Expanding range of customers want to benefit from the value of molecular insights


QIAGEN customer classes

2018 net sales (% of total QIAGEN sales)




Product portfolio

2018 net sales (% of total QIAGEN sales)



Global presence


2018 net sales (% of total QIAGEN sales)



- A most trusted brand found in virtually every lab worldwide
- True hybrid across continuum from Life Sciences to Molecular Diagnostics
- Netherlands holding company, listed on NYSE and Frankfurt Stock Exchange
- ~5,000 employees in over 35 countries

● World leader in molecular testing enabling customers to transform biological samples into valuable insights


Sales by customer class (As % of annual net sales)




● QIAGEN going through transformation to focus on attractive growth opportunities

2020 ambitions


Net sales




Adjusted EPS




Operating cash flow



- 2020 ambitions: Strong growth in sales, adjusted EPS and cash flow



● Supporting our business expansion while increasing returns to shareholders



● Committed to higher returns and greater value creation as differentiated leader



Introducing QIAGEN

Portfolio review

Q1 2019 results

Appendix

Q1 2019 developments

		Life Sciences	Molecular Diagnostics
Precision Medicine	First FDA-approved CDx for new biomarker <i>therascreen</i> FGFR		✓
QuantiFERON	Tecan as second customer option for pre-analytical handling with Hamilton offering		✓
Automation Systems			
QIAstat-Dx	New Meningitis/Encephalitis panel set for EU launch in H2 2019, positive data at ECCMID		✓
NeuMoDx	Goal to expand NeuMoDx content menu to 11 CE-IVD tests for infectious diseases		✓
QIAsymphony	Well on track to achieve end-2019 target of >2,500 cumulative placements	✓	✓
NGS	New solutions to integrate QIAGEN bioinformatics with QIAseq and QIAact panels	✓	✓
Differentiated Technologies	New liquid biopsy sample preparation solutions launched	✓	

● Strengthening our Sample to Insight portfolio to address Life Science and MDx customer demands

Q1 2019 highlights

- *therascreen* FGFR: first FDA approval for key CDx usage
- LabCorp joins QIAGEN's Day-One Lab Readiness program

Selected *therascreen* U.S.-approved CDx assay portfolio


	Drug	Partner
KRAS	Vectibix®	
EGFR	VIZIMPRO®	
	Iressa®	
	GILOTRIF®	
NEW	FGFR	BALVERSA™

Day-One Lab Readiness partners




FGFR: New U.S. CDx assay

- Assay qualifies patients for use of novel therapy from Janssen




● Precision Medicine: Increasing range of QIAGEN companion diagnostics with a new FDA approval



● QIAGEN: Most comprehensive portfolio to address demands for various molecular testing technologies

Addressing the majority of the ~\$4.8 billion Molecular Diagnostics market in 2018




● Since 2015: QIAGEN created a comprehensive automation portfolio addressing MDx key segments


Q1 2019 highlights

- U.S. approval expected in mid-2019 with respiratory panel
 - Gastrointestinal panel to be launched later in 2019
- European rollout building momentum
 - CE-IVD launch of Meningitis/Encephalitis panel planned for H2 2019

Selected menu expansion



QIAstat-Dx Meningitis/Encephalitis panel



● QIAstat-Dx: European commercialization building momentum with plans to add meningitis panel in H2 2019

Q1 2019 highlights

- First wave of instruments placed in Europe
 - Positive customer response to processing speed, random access, ease of use and planned test menu
- Plans for CE-IVD menu expansion to 11 tests by end-2019
 - Priority focus on high-volume tests for infectious diseases

Selected European test menu expansion plan

HCV	✓	Trich + MG	✓
HBV	✓	HIV	✓
CT/NG	✓	FluA / B-RSV	✓
GBS	✓	HPV	✓
		EBV	✓
		GAS	✓
		CMV	✓
		HCV	✓
		HBV	✓
		CT/NG	✓
		GBS	✓


Available
End 2019

 ✓ Available
 ✓ Coming soon

NeuMoDx 96 at ECCMID 2019



● NeuMoDx: Goal of at least 11 tests by year-end on breakthrough integrated molecular testing platform




● The world's first complete Sample to Insight NGS solution for actionable results

Q1 2019 highlights

- Surpassed 60 million tests used worldwide
 - Annual growth of about 12 million tests
- Expanding portfolio of automation options
 - Tecan as second collaboration for tube handling
 - EU rollout under way for DiaSorin LIAISON, on track for U.S. approval during 2019




QuantiFERON-TB automation partners




● **QuantiFERON: Partnering for increased flexibility in automation of globally implemented TB test**

Tuberculin skin test (TST)



- Manual placement, reading, data entry
- Affected by BCG vaccine and NTM
- Two patient visits required
- Significant inter-reader variability
- Poor surveillance tool
- Often no quality control after training



QuantiFERON-TB (QFT)



- Can be fully automated
- Highly specific
- Results with one patient visit
- No inter-reader variability
- Electronic results
- Quality-assured laboratory test⁽¹⁾

QuantiFERON-TB: Leading IGRA with significant clinical and workflow benefits


BCG – Bacillus Calmette-Guerin vaccine NTM – Non-tuberculosis mycobacteria IGRA – Interferon-gamma release assay

(1) Not available in all markets

Q1 2019 highlights

- Launch of new liquid biopsy kits
 - exoRNeasy Kits: Isolation of RNA from extracellular vesicles from biofluids
 - miRNeasy QIAcube HT Kit: Automated purification of cell-free total RNA
- New solutions for universal NGS portfolio and GeneReader NGS System
 - QIAseq and QIAact DNA panels integration with CLC Genomics and QCI-Interpret


Most comprehensive liquid biopsy portfolio



Circulating tumor cells
(DNA)




Exosomes
(DNA / RNA)



Free circulating nucleic acids
(DNA / RNA)

Sample to Insight liquid biopsy solutions for exosomes



Expanding portfolio of novel Sample to Insight solutions in the forefront of key trends



Introducing QIAGEN

Portfolio review

Q1 2019 results

Appendix

1 Achieved Q1 2019 CER outlook for net sales, exceeded adj. EPS

- \$348.7 million net sales (+1.5% actual, +6.1% CER) vs. ~5-6% CER outlook
- \$0.27 adj. EPS (\$0.28 CER) vs. \$0.26-0.27 CER outlook
- 22% adj. operating income margin absorbs QIAstat-Dx U.S. launch prep

2 Advancing our focused Sample to Insight portfolio

- European rollout progressing well for QIAstat-Dx and NeuMoDx
- U.S. approvals for *therascreen* CDx assay with new biomarker FGFR
- QuantiFERON-TB grows 15% CER, new automation options well received
- New research products in liquid biopsy, NGS panels with bioinformatics
- Strong QIAsymphony placements, set for >2,500 cumulative placements

3 New \$100 million share repurchase program commitment


- After completion of current \$200 million program, of which \$50 million remains
- Ongoing commitment to disciplined capital allocation

4 Reaffirming 2019 outlook for sales growth and higher adjusted EPS

- ~+7-8% CER outlook for 2019 full-year net sales growth
- ~\$1.45-1.47 CER outlook for 2019 full-year adjusted EPS
- Includes \$0.03 CER dilution for digital PCR investments


Q1 net sales

(In \$ millions, at actual rates)



Q1 adjusted EPS⁽¹⁾

(In \$ per share)



Outlook – As of May 6, 2019

	Q2 2019	FY 2019
Net sales growth (CER)	~ +5% CER	~ +7-8% CER
<i>Anticipated currency impact⁽²⁾</i>	~ -4 p.p.	~ -3 p.p.
Adj. diluted EPS (CER)	~ \$0.33-0.34 CER	~ \$1.45-1.47 CER
<i>Anticipated currency impact⁽²⁾</i>	~ -\$0.01	~ -\$0.03-0.04

Refer to accompanying tables for reconciliation of reported to adjusted figures.

(1) Weighted number of diluted shares (Q1 2019: 233.6 million, Q1 2018: 232.5 million).

(2) Based on currency rates as of April 30, 2019.

CER – Constant exchange rates

p.p. – percentage points

CDx – Companion diagnostics

NGS – Next-generation sequencing

In \$ millions, unless indicated
(Diluted EPS in \$ per share)

	First quarter		
	2019	2018	Change
Net sales	348.7	343.6	1.5% (6.1% CER)
<i>Gross profit margin</i>	64%	66%	
<i>Adjusted gross profit margin</i>	70%	70%	
Operating income	41.2	47.9	-14%
<i>Operating income margin</i>	12%	14%	
Adjusted operating income	77.9	77.2	1%
<i>Adjusted operating income margin</i>	22%	22%	
Net income	29.5	32.3	-9%
Adjusted net income	62.0	59.6	4%
Tax rate	NM	17%	
Adjusted tax rate	20%	20%	
EPS (\$ per share) ⁽¹⁾	\$0.13	\$0.14	
Adjusted EPS (CER) ⁽¹⁾	\$0.27 (\$0.28)	\$0.26	

Achieved outlook for CER net sales growth, exceeded outlook for adjusted EPS gains

Refer to accompanying tables for reconciliation of reported to adjusted figures.

(1) Weighted number of diluted shares (Q1 2019: 233.6 million, Q1 2018: 232.5 million).

CER – Constant exchange rates NM – Not meaningful

Q1 2019 net sales: \$348.7 million

	Sales (In \$ m)	% change	% CER change	% of sales
Consumables and related revenues	\$313	+2%	+7%	90%
Instruments ⁽¹⁾	\$36	-3%	+2%	10%
Molecular Diagnostics ⁽²⁾	\$168	+4%	+10%	48%
Life Sciences ⁽³⁾	\$181	-1%	+3%	52%
<i>Academia / Applied Testing</i> ⁽³⁾	\$110	-2%	+2%	32%
<i>Pharma</i>	\$71	+1%	+4%	20%

Molecular Diagnostics

- QuantiFERON-TB grows 15% CER, in line with 2019 target range
- Precision Medicine growth from diagnostics co-development projects
- Solid QIA Symphony placements and single-digit CER gains in consumables
- First-time sales from QIAstat-Dx
- Instrument service contract discontinuation reduces MDx sales by ~ 1 p.p.

Life Sciences

- +4% CER growth excl. divestment of veterinary testing assay portfolio (April 2018)
- Mid-single-digit CER gains in instruments, low-single-digit CER growth in consumables and related revenues
- Pharma sales business expansion across all regions
- Academia / Applied Testing sales growth in Americas and Asia-Pacific / Japan region, but ongoing weaker trends in Europe

Q1 2019: Solid performance led by +10% CER growth in Molecular Diagnostics

(1) Instrument excluding services (Q1 2019: +2%, +8% CER)


(2) CDx co-development sales (Q1 2019: \$12 million, +44%, +47% CER).

(3) Changes presentation of Life Science customer class sales as of Q1 2019 due to changes in internal structures.

Sales figures and sales contributions at actual FX rates
Tables may contain rounding differences


Q1 2019 net sales: \$348.7 million

	Sales (In \$ m)	% change	% CER change	% of sales
Americas	\$170	+7%	+8%	49%
Europe / Middle East / Africa	\$109	-6%	+4%	31%
Asia-Pacific / Japan	\$69	+2%	+6%	20%




Americas

Q1 2019: High-single-digit CER growth in the U.S. led regional results, complemented by strong double-digit gains in Brazil that offset weaker trends in Mexico.



Europe / Middle East / Africa

Q1 2019: Overall higher CER sales growth due to solid trends in France, Turkey, United Kingdom and Middle East against weaker results in other western European countries, in particular Germany and Italy.



Asia-Pacific / Japan

Q1 2019: Double-digit CER growth in China complemented by single-digit CER gains in Japan and Singapore against lower sales in South Korea.

Q1 2019: Americas region (+8% CER) and top 7 emerging markets (+23% CER) lead performance

Top 7 EGM (Q1 2019: +9% / +23% CER / 14% of sales); Rest of the world (Q1 2019 less than 1% of net sales)
Sales figures and sales contributions at actual FX rates Tables may contain rounding differences


Balance sheet data

(As of March 31)	2019	2018
Group liquidity (In \$ millions)	780	1,014
Net debt (In \$ millions)	968	759
Shareholder equity ratio	48%	51%
Leverage ratio ⁽¹⁾	1.7x	1.4x

Cash flow

(In \$ millions)	2019	2018
Net cash provided by operating activities ⁽²⁾	44.7	48.2
Purchases of property, plant and equipment	-23.4	-18.9
Free cash flow ⁽²⁾	21.3	29.3

Leverage ratio⁽¹⁾



● Q1 2019: Operating cash flow at \$44.7 million impacted by tax payments and derivative costs

(1) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA.

(2) Net cash provided by operating activities for Q1 2018 included \$30 million payment for pre-paid royalties for Natera partnership.

As of May 6, 2019

Q2 2019 outlook

FY 2019 outlook

Net sales	~5% CER (Prior year: \$377.2 m)	~+7-8% CER (Prior year: \$1,501.8 m)
Adjusted EPS ⁽¹⁾	~\$0.33-0.34 CER (Prior year: \$0.33)	~\$1.45-1.47 CER (Prior year: \$1.34)
<i>Adjustments to operating income (in \$ millions):</i>		
Amortization of acquired intellectual property	~\$29 m	~\$105 m
Restructuring-related items	~\$3 m	~\$8 m
Business integration and acquisition-related items	~\$7 m	~\$26 m
Adjusted tax rate (In %)	~20%	~20-21%
Weighted average number of diluted shares outstanding (Based on \$40.00 share price)	~233 million	~233 million

CER – Constant exchange rates

(1) QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures to provide additional insight into its performance. These results include adjusted gross profit, adjusted operating income, adjusted net income attributable to owners of QIAGEN N.V. and adjusted diluted EPS. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

Every \$1.00 change in market price per share of common stock results in an ~200,000 increase / decrease in dilutive shares due to the call-spread overlay (CSO) as follows: above / below \$38 for 2021 convertible notes, above \$50.97 for the 2023 convertible notes and above \$52.16 for the 2024 convertible notes.



Achieved Q1 2019 sales outlook, exceeded adj. EPS (at CER)

Delivering solid performance while supporting QIAstat-Dx

New \$100 million share repurchase program commitment

2019: On track for higher sales and adjusted EPS (at CER)

ECCMID 2019 conference, Amsterdam



American Association of Cancer Research Annual Meeting, Atlanta, GA

Appendix

Q1 2019: Consolidated Statements of Income (unaudited)

(In \$ thousands, except share data)	Three months ended March 31, 2019	Three months ended March 31, 2018
Net sales	348,654	343,568
Cost of sales	123,814	117,894
Gross profit	224,840	225,674
Operating expenses:		
Research and development	40,788	39,522
Sales and marketing	95,886	96,079
General and administrative, restructuring, integration and other	37,688	31,951
Acquisition-related intangible amortization	9,326	10,180
Total operating expenses	183,688	177,732
Income from operations	41,152	47,942
<i>Adjusted income from operations</i>	77,913	77,246
Other income (expense):		
Interest income	8,088	4,674
Interest expense	(20,390)	(15,020)
Other (expense) income, net	(392)	1,547
Total other expense, net	(12,694)	(8,799)
Income before income taxes	28,458	39,143
<i>Adjusted income before income taxes</i>	77,180	74,097
Income taxes	(1,062)	6,848
<i>Adjusted income tax</i>	15,166	14,498
Net income	29,520	32,295
<i>Adjusted net income</i>	62,014	59,599
Diluted net income per common share	\$0.13	\$0.14
<i>Adjusted diluted net income per common share</i>	\$0.27	\$0.26
Diluted shares used in computing diluted net income per common share (in thousands)	233,607	232,533

Q1 2019: Reconciliation adjusted results

In \$ millions (Except EPS) (unaudited)	Net sales	Gross profit	Operating income	Pretax income	Income tax	Tax rate	Net income	Diluted EPS
First quarter 2019								
Reported results	348.7	224.8	41.2	28.5	1.1	NM	29.5	0.13
<i>Adjustments</i>								
Business integration, acquisition and restructuring-related items (including litigation)		0.9	10.0	10.0	-2.7		7.3	0.03
Purchased intangibles amortization		17.5	26.8	26.8	-6.9		19.9	0.09
Non-cash interest expense charges				11.9			11.9	0.05
Other special income and expense					-6.7		-6.7	-0.03
Total adjustments		18.4	36.8	48.7	-16.3		32.5	0.14
Adjusted results	348.7	243.2	77.9	77.2	-15.2	20%	62.0	0.27

NM – Not meaningful
Table may have rounding differences.

	Net sales (In \$ millions)	Net sales (CER)	Currency exposure (As % of CER sales)	Change (In \$ millions)
First quarter 2019				
U.S. dollar	168.7	168.7	46%	0.0
Euro	67.5	73.1	20%	-5.6
British pound	17.8	19.0	5%	-1.2
Japanese yen	16.0	16.3	5%	-0.3
Other currencies	78.7	87.4	24%	-8.7
Total net sales	348.7	364.5	100%	-15.8

CER - Constant exchange rates

Other currencies include CAD, DKK, TRY, SEK, CHF, AUD, BRL, CNY, MYR, SGD, KRW, HKD, MXN, INR, TWD, RUB, THB and ZAR

2019: Quarterly and full-year income statement summary

(In \$ millions, unless indicated) (Diluted EPS in \$ per share)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	YTD 2019	
Net sales	348.7				348.7	
Net sales (CER)	364.5				364.5	
Gross profit	224.8				224.8	
<i>Gross profit margin</i>	64%				64%	
Adjusted gross profit	243.2				243.2	
<i>Adjusted gross profit margin</i>	70%				70%	
Operating income	41.2				41.2	
<i>Operating margin</i>	12%				12%	
Adjusted operating income	77.9				77.9	
<i>Adjusted operating margin</i>	22%				22%	
Tax rate	-4%				-4%	
Adjusted tax rate	20%				20%	
Net income	29.5				29.5	
Adjusted net income	62.0				62.0	
Diluted EPS	0.13				0.13	
Adjusted diluted EPS (CER) (\$ per share)	0.27	(0.28)			0.27	(0.28)
Diluted shares outstanding for EPS calculation	233.6				233.6	

CER - Constant exchange rates

Table may have rounding differences. Refer to accompanying tables for reconciliation of reported to adjusted figures.

Net sales by customer class

(In \$ millions at actual rates / change in actual, CER rates)

	Q1 2019			Q2 2019			Q3 2019			Q4 2019			YTD 2019		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Molecular Diagnostics	168	4%	10%										168	4%	10%
Life Sciences	181	-1%	3%										181	-1%	3%
<i>Academia / Applied Testing</i>	110	-2%	2%										110	-2%	2%
<i>Pharma</i>	71	1%	4%										71	1%	4%

Net sales by region

(In \$ millions at actual rates / change in actual, CER rates)

	Q1 2019 ⁽¹⁾			Q2 2019			Q3 2019			Q4 2019			YTD 2019 ⁽¹⁾		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Americas	170	7%	8%										170	7%	8%
Europe / Middle East / Africa	109	-6%	4%										109	-6%	4%
Asia-Pacific / Japan	69	2%	6%										69	2%	6%

(1) Rest of World contributed less than 1% of net sales in Q1 2019 and YTD 2019

Tables may contain rounding differences Does not exclude sales of products affected by business portfolio changes

(In \$ thousands, except par value)	March 31, 2019	December 31, 2018	(In \$ thousands, except par value)	March 31, 2019	December 31, 2018
Assets	(unaudited)		Liabilities and Equity	(unaudited)	
Current assets:			Current liabilities:		
Cash and cash equivalents	552,857	1,159,079	Current portion of long-term debt	351,201	503,116
Short-term investments	227,534	234,606	Accounts payable	63,237	69,415
Accounts receivable, net	341,445	351,612	Fair value of derivative instruments – current	159,841	106,594
Income taxes receivable	43,339	34,936	Accrued and other current liabilities	341,604	263,017
Inventories, net	167,093	162,912	Income taxes payable	27,958	30,047
Fair value of derivative instruments – current	159,956	102,754	Total current liabilities	943,841	972,189
Prepaid expenses and other current assets	106,436	109,161	Long-term liabilities:		
Total current assets	1,598,660	2,155,060	Long-term debt	1,397,553	1,671,090
Long-term assets:			Deferred income taxes	49,800	63,411
Property, plant and equipment, net	511,438	511,659	Fair value of derivative instruments – long-term	248,542	317,393
Goodwill	2,114,251	2,108,536	Other long-term liabilities	174,572	89,279
Intangible assets, net	709,361	475,043	Total long-term liabilities	1,870,467	2,141,173
Deferred income taxes	32,850	42,896	Equity:		
Fair value of derivative instruments – long-term	234,137	295,363	Common shares, EUR 0.01 par value:		
Other long-term assets	219,667	159,775	Authorized – 410,000 shares	2,702	2,702
Total long-term assets	3,821,704	3,593,272	Issued – 230,829		
Total assets	5,420,364	5,748,332	Additional paid-in capital	1,722,185	1,742,191
			Retained earnings	1,342,409	1,379,624
			Accumulated other comprehensive loss	(318,604)	(310,644)
			Less treasury shares at cost – 3,863 shares (2019) and 5,320 shares (2018)	(142,636)	(178,903)
			Total equity	2,606,056	2,643,970
			Total liabilities and equity	5,420,364	5,748,332



Consolidated Statements of Cash Flows (unaudited)

(In \$ thousands)	Three months ended		(In \$ thousands)	Three months ended	
	March 31, 2019	March 31, 2018		March 31, 2019	March 31, 2018
Cash flows from operating activities:			Cash flows from financing activities:		
Net income	29,520	32,295	Repayment of long-term debt	(433,400)	-
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:			Principal payments on capital leases	-	(349)
Depreciation and amortization	59,260	52,914	Proceeds from issuance of common shares	571	292
Non-cash impairments	114	-	Tax withholdings related to vesting of stock awards	(2,307)	-
Deferred income taxes	(1,067)	(1,308)	Purchase of treasury shares	(44,373)	-
Other items, net including fair value changes in derivatives	22,504	17,246	Other financing activities	(895)	(2,136)
Change in operating assets	(5,599)	(24,126)	Net cash used in financing activities	(480,404)	(2,193)
Change in operating liabilities	(59,998)	(28,806)	Effect of exchange rate changes on cash and cash equivalents	44	2,659
Net cash provided by operating activities	44,734	48,215	Net (decrease) increase in cash and cash equivalents	(606,222)	157,209
Cash flows from investing activities:			Cash and cash equivalents, beginning of period	1,159,079	657,714
Purchases of property, plant and equipment	(23,409)	(18,898)	Cash and cash equivalents, end of period	552,857	814,923
Purchases of intangible assets	(129,379)	(15,200)	Reconciliation of Free Cash Flow⁽¹⁾		
Purchases of investments	(4,296)	(3,091)	Net cash provided by operating activities	44,734	48,215
Cash paid for acquisitions, net of cash acquired	(24,371)	-	Purchases of property, plant and equipment	(23,409)	(18,898)
Purchases of short-term investments	-	(84,590)	Free Cash Flow	21,325	29,317
Proceeds from redemptions of short-term investments	5,239	246,668			
Cash received (paid) for collateral asset	5,610	(13,690)			
Other investing activities	10	(2,671)			
Net cash (used in) provided by investing activities	(170,596)	108,528			

(1) Free cash flow is a non-GAAP financial measure and is calculated from cash provided by operations reduced by purchases of property, plant and equipment. QIAGEN believes this is a common financial measure useful to further evaluate the results of operations.

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total Q1 2019	Total Q1 2018	Change
Production	292	738	146	1,176	1,053	12%
R&D	212	733	50	995	967	3%
Sales	555	750	693	1,998	1,876	7%
Marketing	85	159	81	325	270	20%
Administration	103	330	135	568	508	12%
Total	1,247	2,710	1,105	5,062	4,674	8%

Headcount information is made using certain assumptions regarding role and function. During 2018, these assumptions were updated and their classifications were changed accordingly.

Adj	Adjusted
AIV	Avian influenza virus
ALK	Anaplastic Lymphoma Kinase
AML1	Acute Lymphoblastic Leukemia
ASR	Analyte Specific Reagent
AUD	Australian Dollar
BAALC	Brain and Acute Leukemia, Cytoplasmic
BRCA	Breast Cancer gene
BCR-ABL	Breakpoint cluster region-abelson
BRAF	Serine/Threonine-Protein Kinase B-Raf
BRL	Brazilian Real
BKV	BK Virus
BVDV	Bovine Virus Diarrhea
C. Diff	Clostridium Difficile
CAD	Canadian Dollar
CDx	Companion diagnostics
CE	European Conformance Mark
CER	Constant Exchange Rates
CHF	Swiss Franc
CLLU1	Chronic Lymphocytic Leukemia
CMV	Cytomegalovirus
CNY	China Yuan Renminbi
CRC	Colorectal Cancer
CSFV	Classical Swine Fever Virus
CT	Chlamydia Trachomatis
DKK	Danish Krona
DNA	Deoxyribonucleic acid
EBITDA	Earnings before Interest, Taxes, Depreciation and Amortization
EBV	Epstein-Barr virus
EGFR	Epidermal Growth Factor Receptor
EGM	Emerging Growth Markets
EPS	Earnings per share
EU	European Union
ESBL	Extended Spectrum Beta

EUR	Euro
FDA	Food and Drug Administration
FX	Foreign exchange
GAAP	Generally Accepted Accounting Principles
GAS	Group A Streptococcus
GBP	British Pound
GBS	Group B Streptococcal Septicemia
GMO	Genetically Modified Organism
HAV	Hepatitis A Virus
HBV	Hepatitis B Virus
HCV	Hepatitis C virus
HCMV	Human cytomegalovirus
HEV	Hepatitis E Virus
HIV	Human Immunodeficiency Virus
HSV	Herpes Simplex Virus
HPV	Human Papillomavirus
HSV 1/2	Herpes Simplex Virus 1 and 2
IDH 1/2	Isocitrate Dehydrogenase 1 and 2
Iq	Institute for Product Quality
IVD	In Vitro Diagnostic
INR	Indian Rupee
IP	Intellectual Property
JAK2	Janus Kinase 2
JPY	Japan Yen
KRAS	Kirsten rat Sarcoma Viral Oncogene Homolog
KRW	South Korean Won
LATAM	Latin America
LDT	Laboratory Developed Tests
LIS	Laboratory information system
MG	Mycoplasma genitalium
MGMT	Methylguanine-methyltransferase
Mg/Ms	Mycoplasma Mg/Ms
MDx	Molecular Diagnostics
MN1	Meningioma 1

MP	Mycoplasma Pneumonia
MRSA	Methicillin-Resistant Staphylococcus Aureus
MTB	Mycobacterium Tuberculosis
MPL	Myeloproliferative leukemia
NG	Neisseria Gonorrhoeae
NGS	Next Generation Sequencing
NPM1	Nucleophosmin
NIH	National Institutes of Health
N.M.	Not Meaningful
NRAS	Neuroblastoma RAS-viral
PCR	Polymerase chain reaction
PI3K	Phosphoinostide 3-kinase
PP&E	Property, plant and equipment
QFT	QuantiFERON
R&D	Research & Development
RoW	Rest of World
RGQ	Rotor-Gene Q
RNA	Ribonucleic Acid
ROM	Rupture of Fetal Membranes
RSV	Respiratory syncytial virus
RUO	Research Use Only
SARS	Severe Acute Respiratory Syndrome
SBV	Schmallenberg Virus
STI	Sexually transmitted infection
VZV	Varicella-Zoster Virus
TB	Tubercle Bacillus
THB	Thai Baht
Trich	Trichomoniasis
TRY	Turkish New Lira
UGT1A1	UDP-glucuronosyltransferase 1-1
USD	U.S. Dollar
UU	Ureaplasma Urealyticum
WGA	Whole Genome Amplification
ZAR	South African Rand



John Gilardi
Vice President
Corporate Communications and IR

Phone: +49 2103 29 11711
+1 240 686 2222
Mobile: +49 152 018 11711

E-mail: john.gilardi@qiagen.com

E-mail: ir@qiagen.com
Internet: ir.qiagen.com



Phoebe Loh
Associate Director
Investor Relations

Phone: +49 2103 29 11457
Mobile: +49 152 018 11457

E-mail: phoebe.loh@qiagen.com

www.linkedin.com/company/qiagen
 www.facebook.com/QIAGEN




Alexandra Koenig
Coordinator
Investor Relations

Phone: +49 2103 29 11709
Mobile: +49 152 018 11709

E-mail: alexandra.koenig@qiagen.com

twitter.com/QIAGEN
 www.youtube.com/user/QIAGENvideos

Download the QIAGEN IR App



Share information

NYSE:	QGEN
Frankfurt:	QIA
ISIN / CUSIP:	NL0012169213 / N72482 123
WKN:	A2D KCH

QGEN
LISTED
NYSE

Calendar

Annual General Meeting	June 17, 2019
Investor Day (New York)	June 20, 2019
Q2 2019 results	July 2019
Q3 2019 results	November 2019